Drug screening using model systems: some basics.
An increasing number of laboratories that focus on model systems are considering drug screening. Executing a drug screen is complicated enough. But the path for moving initial hits towards the clinic requires a different knowledge base and even a different mindset. In this Editorial I discuss the importance of doing some homework before you start screening. 'Lead hits', 'patentable chemical space' and 'druggability' are all concepts worth exploring when deciding which screening path to take. I discuss some of the lessons I learned that may be useful as you navigate the screening matrix.
Icahn School of Medicine at Mount Sinai, Annenberg 25-40, Campus Box 1020, 1468 Madison Avenue, New York, NY 10029, USA ross.cagan@mssm.edu.
Ross
0000-0001-5297-450X
R
Cagan
D000818:Animals; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018973:Intellectual Property; D023421:Models, Animal; D010330:Patents as Topic